Stergios Kechagias

Long‐term follow‐up of patients with NAFLD and elevated liver enzymes†‡

Mattias Ekstedt, Lennart Franzén, Ulrik Mathiesen et al. · Hepatology · 2006 · 2.3K citations

Medicine, Pathology, Clinical Epidemiology +16

Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up

Mattias Ekstedt, Hannes Hagström, Patrik Nasr et al. · Hepatology · 2014 · 2.3K citations · Full text

Medicine, Internal Medicine, Pathology +17

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

Medicine, Internal Medicine, Pharmacology +8

Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD

Hannes Hagström, Patrik Nasr, Mattias Ekstedt et al. · Journal of Hepatology · 2017 · 1.1K citations

Medicine, Internal Medicine, Pathology +15

Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆

Quentin M. Anstee, Rebecca Darlay, Simon Cockell et al. · Journal of Hepatology · 2020 · 514 citations · Full text

Medicine, Genetics, Molecular Genetics +13